Skip to main content
ALLR
NASDAQ Life Sciences

Allarity Q3 10-Q Flags Going-Concern Doubt and Nasdaq Equity Deficiency

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.95
Mkt Cap
$14.539M
52W Low
$0.769
52W High
$1.84
52W Position info
24% above low
Off High info
48% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ALLR sits 24% above its 52-week low of $0.769.

Summary

Allarity's Q3 2026 10-Q discloses substantial doubt about its ability to continue as a going concern and negative stockholders' equity that breaches Nasdaq's $2.5M minimum, with a post-quarter $3.0M debt-to-preferred conversion cited as restoring compliance.


Key Events · Earnings and Guidance · ALLR

  • Going-Concern Warning Disclosed

    Management states substantial doubt about the company's ability to continue as a going concern within one year; $24.1M of cash and restricted cash as of September 30, 2026 may not fund operations for twelve months, and $10.0M of that is restricted as collateral for the B Note.

  • Negative Equity Breaches Nasdaq Rule

    Stockholders' equity was $(2.3)M at September 30, 2026, below Nasdaq Capital Market Rule 5550(b)(1)'s $2.5M minimum; a deficiency notice could follow and require a compliance plan.

  • Losses and Interest Expense Widen

    Q3 2026 net loss was $6.2M versus $2.8M a year earlier, and nine-month net loss $12.4M versus $7.9M; interest expense rose to $1.96M from $126K after the March 2026 Streeterville notes, which carried $21.6M at quarter-end.

  • R&D Jump on Phase 3 Manufacturing

    Research and development expense rose to $4.2M in Q3 2026 from $1.2M, including a one-time $3.2M charge for Phase 3 drug manufacturing materials expensed at delivery.


Analysis · ALLR · Life Sciences

Allarity's Q3 report carries an explicit going-concern warning: with $24.1M of cash and restricted cash — $10.0M of which is locked up as collateral for the Streeterville B Note — management says it may not fund operations for the next twelve months. The company also ended the quarter with negative stockholders' equity of $(2.3)M, below Nasdaq's $2.5M continued-listing threshold, which puts a deficiency notice and potential delisting in play unless equity is rebuilt. Losses are widening ($12.4M for nine months versus $7.9M a year earlier) and interest expense has ballooned to $1.96M from $126K after the March 2026 $20M Streeterville financing. The one offset is a November 12, 2026 deal converting $3.0M of the A-1 Note into Series B Preferred Stock, which the company says pushes stockholders' equity back above $2.5M — a fix that trades debt for preferred equity rather than bringing in new cash.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALLR was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.5M. The 52-week trading range was $0.77 to $1.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALLR - Latest Insights

ALLR
Nov 13, 2026, 8:07 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.915 info
Change: -$0.035 (-4%) info
Market Cap: $14.539M info
ALLR
Nov 02, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8415
Real-time Price: $0.915 info
Change: +$0.0735 (+9%) info
Market Cap: $14.539M info
ALLR
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.870
Real-time Price: $0.915 info
Change: +$0.045 (+5%) info
Market Cap: $14.539M info
ALLR
Sep 14, 2026, 12:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.21
Real-time Price: $0.915 info
Change: -$0.295 (-24%) info
Market Cap: $14.539M info
ALLR
Aug 14, 2026, 8:02 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $0.915 info
Change: -$0.5072 (-36%) info
Market Cap: $14.539M info